Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 26 2023 - 4:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2023 (Report No.2)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into
English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
CONTENTS
On December 26, 2023, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira™ Announces 95% Accuracy Results for
HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024,” a copy of which is furnished as Exhibit 99.1 with this
report of foreign private issuer on Form 6-K.
The
Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements
on Form F-3 (Registration No. 333-266748) and Form S-8 (Registration No. 333-259057), filed with the Securities and
Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Inspira Technologies Oxy B.H.N. Ltd. |
|
|
|
Date: December 26, 2023 |
By: |
/s/ Dagi Ben-Noon |
|
|
Name: |
Dagi Ben-Noon |
|
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Inspira™
Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
RA’ANANA,
Israel, December 26, 2023 – Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company”
or “Inspira”), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today
announced a significant advancement in its sensor technology by its team of experts. This breakthrough, in achieving 95% accuracy compared
to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer
systems used in hospitals that typically require intermittent blood draws. This advancement signals Inspira’s potential entry into the
disposables market.
The
development of the first HYLATM variant, key to
this advancement, marks a significant step towards its submission under a 510(k) pathway with the U.S. Food & Drug Administration
(“FDA”), which is expected in the second half of 2024. This sensor technology is designed to be integrated with the Company’s
INSPIRA ART100 and was submitted to the FDA in September 2023, with clearance anticipated in the first half of 2024.
The
HYLATM Blood Sensor line (the “Blood Sensor”)
is set to transform intensive care unit (ICU) operations, offering continuous, real-time blood data collection and analysis. This enhances
patient care with critical insights and alerts, with the aim to improve medical procedures and device efficiency.
Key features
of the Blood Sensor include:
| ● | High
Accuracy: Achieves 95% accuracy relative to standard blood gas analyzers; |
| ● | Non-invasive:
Eliminates the need for blood draws; |
| ● | Durability:
Built to handle ICU and operating room environments; |
| ● | Versatility:
Compatible with various medical procedures, including: the cardio pulmonary bypass, extracorporeal
membrane oxygenation, continuous renal replacement therapy, and dialysis; and |
| ● | Modular
Design: Engineered to complement existing medical devices, targeting the two-million annual
open-heart surgery patients globally. |
In
developing the HYLATM Blood
Sensor line, Inspira utilizes in-house lab testing as well as hospital collaborations for the purpose of clinical research and development.
This approach has enabled to define the Blood Sensor’s disposable materials and methods, with HYLA’s planned razor blade
business model. While primarily designed for INSPIRA ART devices, plans are underway
also to offer a variant of the Blood Sensor as a standalone device.
Dagi
Ben-Noon, CEO of Inspira Technologies, commented: “With our sensor technology, we are not only enriching our INSPIRA ART device
line but also forging a path into the disposables market, setting the stage for groundbreaking developments in healthcare.”
Inspira Technologies OXY BHN Ltd.
Inspira
Technologies is leading the way in transforming life-support care. Its innovative solutions are paving the way for direct blood oxygenation,
bypassing the lungs, and potentially reducing the need for traditional mechanical ventilation. Beyond this, the Company is committed to
advancing blood circulation technology and incorporating AI-driven monitoring systems. These advancements are part of its strategy to
offer more patient-focused, data-informed care. The integration of these technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in respiratory care.
For more information, please
visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements under US Federal securities laws. These forward-looking statements and their implications are based only on
the current expectations of the management of the Company. They are subject to several factors and uncertainties that could cause results
to differ materially from those described in the forward-looking statements. For example, the Company uses forward-looking statements
when it discusses the Company’s vision to supersede traditional mechanical ventilators, the expected timeline for FDA submissions
and potential FDA approvals of its devices, the expected benefits and accuracy of its devices and the belief that with this new
sensor technology, it is not only enriching its ART device lineup but also forging a path into the disposables market, setting the stage
for groundbreaking developments in healthcare. Except as otherwise required by law, the Company undertakes no obligation to publicly
release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or the occurrence of
unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
“Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2022, filed with the
SEC, which is available on the SEC’s website, www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies
OXY B.H.N. LTD., All rights reserved.
MRK-ARS-080
Inspira Technologies Oxy... (NASDAQ:IINN)
Historical Stock Chart
From Apr 2024 to May 2024
Inspira Technologies Oxy... (NASDAQ:IINN)
Historical Stock Chart
From May 2023 to May 2024